Clinical Trials Logo

Vascular Diseases clinical trials

View clinical trials related to Vascular Diseases.

Filter by:

NCT ID: NCT05654935 Withdrawn - Stroke Clinical Trials

Telerobotic Ultrasound for Carotid Imaging - Feasibility Study

Start date: March 26, 2014
Phase:
Study type: Observational

In this proposal, the investigators will demonstrate the feasibility and noninferiority of telerobotic ultrasonography as compared to traditional manual acquisition in performing a limited carotid Duplex examination and in carotid plaque detection.

NCT ID: NCT05654233 Not yet recruiting - Clinical trials for Varicose Veins of Lower Limb

The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether adding sulodexide to the patients with varicose veins who received radiofrequency ablation combined with sclerotherapy can reduce or improve the impact of adverse events。

NCT ID: NCT05639660 Recruiting - Clinical trials for Polypoidal Choroidal Vasculopathy

Clinical Implication of Aflibercept in PCV Treatment in China

Start date: January 1, 2021
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to evaluate the overall treatment characteristics and efficacy of Aflibercept in the treatment of PCV in China through a multicenter, observational, prospective-retrospective study. This study is a long-term follow-up cohort, plans to unite a total of 30 hospitals in different regions of the China to enroll 1000 PCV patients. Main evaluation indicators: To observe the changes in visual acuity (BCVA) in PCV patients treated with Aflibercept to evaluate the effectiveness of the treatment.

NCT ID: NCT05624255 Not yet recruiting - Vascular Diseases Clinical Trials

Correlating the Measure of Retinal Vascular Density Through Angio-OCT With Calcium Score

ANOSCA
Start date: November 2022
Phase: N/A
Study type: Interventional

Recent case-control studies have proven that the retinal vascularization mirrors the cardiac vascularization: more the coronary network is altered, more the density of retinal vessels is reduced. No studies have yet been realised in primary prevention. This study aims to demonstrate a link between the density of the retinal vascularization and the calcium score, which is currently the gold standard for the classification of cardiovascular risk in primary prevention. Thus, a simple image of the retinal vascularization could predict the cardiovascular risk of a patient. OCT angiography would become a major aid in the classification of cardiovascular risk in asymptomatic patients.

NCT ID: NCT05620186 Recruiting - Vascular Diseases Clinical Trials

PROficiency Based StePwise Endovascular Curricular Training: Multicentric Registry

PROSPECT
Start date: October 17, 2017
Phase: N/A
Study type: Interventional

The goal of this multicentric registry is to gather data from trainees completing PROSPECT: a PROficiency Based StePwise Endovascular Curricular Training to obtain basic cognitive and technical skills. The main goals are to identify if: - Results from a previous randomised controlled trail can be reproduced in real life. - Evaluate skills retention after program completion. - Assess real life implementation of the training program.

NCT ID: NCT05614193 Recruiting - Vascular Diseases Clinical Trials

Deep Enhanced Imaging in Stroke and Vascular Neurology

Start date: December 1, 2022
Phase:
Study type: Observational

To investigate the performance of enhanced computed tomography (CT) or magnetic resonance (MR) imaging by deep learning relative to conventional CT or MR imaging in brain stroke and vascular neurology. We expect that the deep enhanced imaging method can shorten the time stay in the imaging session of stroke patients, optimize the overall imaging quality and improve the patients' care in imaging session.

NCT ID: NCT05598359 Not yet recruiting - Aging Clinical Trials

TA-65 and Aging Associated Microvascular Dysfunction

Start date: January 1, 2025
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test whether activation of telomerase with a dietary supplement (TA-65) improves microvascular function.

NCT ID: NCT05596760 Recruiting - Quality of Life Clinical Trials

Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers

PICSI-M
Start date: September 11, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to improve communication among clinicians, patients with memory problems, and their family members. We are testing a way to help clinicians have better conversations to address patients' goals for their healthcare. To do this, we created a simple, short guide called the "Jumpstart Guide." The goal of this research study is to show that using this kind of guide is possible and can be helpful for patients and their families. Patients' clinicians may receive a Jumpstart Guide before the patient's clinic visit. Researchers will compare patients whose clinician received a Jumpstart Guide to patients whose clinician did not receive a guide to see if more patients in the Jumpstart Guide group had conversations about the patient's goals for their healthcare. Patients and their family members will also be asked to complete surveys after the visit with their clinician.

NCT ID: NCT05561556 Recruiting - Hypertension Clinical Trials

Mitochondria Oxidative Stress and Vascular Health Study

MOVHS
Start date: December 6, 2022
Phase: N/A
Study type: Interventional

Cardiovascular diseases (CVDs) are the number one cause of death in America and most of the post-industrial world. Hypertension is a leading risk factor for CVDs including stroke, myocardial infarction, and heart failure. Black Americans suffer from the highest rates of hypertension of any racial/ethnic group in America, among the highest in the world. There are also well-documented racial disparities in vascular dysfunction (e.g., endothelial dysfunction, arterial stiffening). Thus, racial disparities in hypertension and vascular dysfunction exacerbate the burden of CVDs, with Black Americans being 30% more likely to die from CVD than any other race in the US. It is established that mitochondrial dysfunction contributes to vascular dysfunction. However, there is a knowledge gap regarding whether targeting mitochondrial dysfunction attenuates oxidative stress, vascular dysfunction, and CVD risk among Black adults at heightened CVD risk. Thus, the investigators will conduct an 8-week trial with the mitochondrial antioxidant MitoQ in middle-aged and older Black and non-Black adults. Our overarching hypothesis is that mitochondrial dysfunction contributes to heightened oxidative stress, vascular dysfunction, and higher BP in Black adults; and that MitoQ will attenuate these racial differences. Importantly, the investigators will also assess social determinants of health (e.g., income, neighborhood disadvantage, discrimination) and health behaviors (e.g., diet, physical activity) and uncover their role in oxidative stress, vascular function, and BP Regarding methodology, the investigators will perform blood draws, vascular testing, preceding and following an 8-week, 20mg daily consumption of MitoQ and placebo. The investigators will also measure urine biomarkers of kidney function and blood pressure in adults (45-75 years old).

NCT ID: NCT05524896 Completed - Vascular Diseases Clinical Trials

Elucidate Vasodilatory Capacity From Histology-Defined Analysis of Coronary CT Angiography

HD-FFRct
Start date: January 1, 2017
Phase:
Study type: Observational

Coronary CT Angiography (CCTA) may be an ideal modality to fill gaps in understanding the extent and rate of progression coronary artery disease. The investigators have developed an image analysis software ElucidVivo that estimates relevant indices, including fractional flow reserve (FFR) . In this study, the investigators aim to assess the value of ElucidVivo-based plaque morphology characterization for predicting non-invasive FFR in patients with suspected coronary artery disease (CAD) who had undergone clinically indicated coronary CTA and invasive coronary angiography (ICA) for physical FFR measurement.